Eli Lilly profit doubles as drug sales rise

INDIANAPOLIS ? Eli Lilly & Co. said Monday its first-quarter profit doubled on sales of depression treatment Cymbalta and impotence drug Cialis, as well as fewer charges, but results missed Wall Street expectations.
From: www.thestar.com

Sector Wrap: Cost cuts, weak dollar drive pharma earnings

The week saw a flurry of quarterly earnings reports from the pharmaceutical sector, many marred by lower revenue in the face of rising generic competition.
From: biz.yahoo.com

Sector Snap: Schering-Plough, Glaxo boost pharma stocks

Positive earnings reports from Schering-Plough Corp. and GlaxoSmithKline PLC lifted big pharma stocks Wednesday after several days of mixed results from their peers.
From: biz.yahoo.com

Wyeth profit hurt by generics

Wyeth posted slightly lower first-quarter earnings on Tuesday, hurt by the recent launch of generic forms of its Protonix ulcer drug, but surprisingly strong sales of other medicines enabled the company to beat Wall Street profit forecasts.
From: news.yahoo.com

Wyeth profit slips, hurt by generic Protonix

Wyeth on Tuesday said its first-quarter net profit fell slightly, hurt by the sudden launch early this year of a generic form of its Protonix ulcer drug, but surprisingly strong sales enabled the company to beat Wall Street profit forecasts.
From: news.yahoo.com

Eli Lilly Profit Doubles on Higher Sales

First-quarter earnings jumped to $1.06 billion, helped by strong sales of Lilly?s Cymbalta and Cialis drugs, but the results missed Wall Street expectations.
From: biz.yahoo.com

Eli Lilly 1Q profit doubles, but falls short of expectations

Drug maker Eli Lilly and Co. said strong sales for Cymbalta and Cialis helped double its first-quarter profit, but results missed Wall Street expectations.
From: news.yahoo.com

Eli Lilly says fewer charges, higher sales of Cialis, Cymbalta help push earnings higher

INDIANAPOLIS - Eli Lilly says first-quarter profit doubled on strong growth in sales of depression treatment Cymbalta and impotence drug Cialis, as well as fewer charges.
From: www.startribune.com

St. Jude wins patent on depression treatment

St. Jude Medical Inc. said Monday it was awarded a patent for a treatment it has developed for depression. (STJ)
From: www.bizjournals.com

Analysts: Drug maker earns get temporary lift amid problems

Major drug companies saw their bottom lines buoyed by a weak dollar, one-time gains and other temporary items, but their shares still fell because of basic economic problems hurting the industry.
From: news.yahoo.com

Eli Lilly 1Q profit doubles as Cialis, Cymbalta sales rise

INDIANAPOLIS - Eli Lilly & Co. said Monday its first-quarter profit doubled on sales of depression treatment Cymbalta and impotence drug Cialis, as well as fewer charges, but results missed Wall Street expectations.
From: nwitimes.com

Talk Therapy Proves Effective for Terminal Cancer Patients

FRIDAY, April 18 (HealthDay News) -- Talk therapy can help treat depression symptoms in patients with terminal cancer, according to Japanese researchers who reviewed the results of six studies that included a total of 517 patients with incurable cancer and depression.
From: news.yahoo.com

Earnings Preview: Eli Lilly seen posting positive 1Q results

Eli Lilly & Co. reports earnings for the first quarter on Monday. The following is a summary of key developments and analyst opinion related to the period.
From: biz.yahoo.com

Depression: Treatment can help

We all get sad now and again. But for people who suffer from depression, this sadness is chronic and persistent. Depression can affect anyone of any race, age, economic status or profession.
From: www.middlesborodailynews.com

Frisco mother fights to stop postpartum depression bill

Giving birth is both a painful and joyous experience for new moms, and for Frisco resident Amy Philo it was no different.
From: www.friscoenterprise.com

Forest Laboratories Swings to 4Q Profit

Drug developer Forest Laboratories Inc. said Tuesday it swung to a fiscal fourth-quarter profit from a year-ago period which included a hefty charge for the buyout of Cerexa Inc.
From: biz.yahoo.com

Mental Health Issues Take Center Stage at DMEC Show

MINNEAPOLIS--Companies could show a significant increase in productivity if they actively screen and treat depression among their employees, according to a study funded by the National Institute of Mental Health and published in the Journal of the American Medical Association.
From: www.riskandinsurance.com

AFX UK Focus) 2008-04-15 13:14 GMT: Forest Labs 4Q net income $172.8M vs year-ago loss $237.9M

NEW YORK (Thomson Financial) - Forest Laboratories Tuesday reported fiscal fourth-quarter earnings of $172.8 million, or 55 cents a share, up from a year-ago loss of $237.9 million, or 75 cents a share.
From: www.iii.co.uk

JOEM Presents Special Report on Depression in the Workplace

This special issue of JOEM, the official publication of ACOEM, presents an update on workplace depression, highlighting the need for an integrated, evidence-based approach to managing this common, chronic, and often recurrent disorder.
From: www.newswise.com

AFX UK Focus) 2008-04-15 16:38 GMT: Danish shares close higher; Novozymes down on broker downgrade UPDATE

(updating with full report)
From: www.iii.co.uk

Forest Labs Guides for 2009 Below Street

Forest Laboratories Inc. on Tuesday guided for fiscal 2009 income and revenue below Wall Street expectations, as the drug developer plans to ramp up research spending.
From: biz.yahoo.com